A case with alopecia related to risperidone use (original) (raw)
Related papers
Quetiapine Induced Hair Loss in an Adolescent Case
Anatolian Journal of Psychiatry, 2014
Hair loss is a frequently seen side-effect of psychotropic medicaments. Beside the psychotropic medicaments valproic acid and lithium, mostly blamed for alopecia, also cases due to use of antidepressants and typical/atypical antipsychotics have been reported. However, studies on alopecia caused by atypical antipsychotic drugs are scarce and limited by case reports. In this paper, a 16-year-old adolescent female patient developing diffuse alopecia associated with use of quetiapine and recovering after cessation of the medicament is presented. As far as we know, this is the first case reporting quetiapine-associated alopecia in an adolescent.
Indian Journal of Pharmacy Practice
Hair loss (alopecia) is an occasional side effect associated with psychotropic drugs use. Fluvoxamine is a synthetic antidepressant which acts as a selective serotonin reuptake inhibitor as well as sigma-1 receptor agonist. Psychotropic drugs are considered to cause hair loss by affecting the telogenic phase of hair follicle. Here we present a case of a 28 year old male patient reported with diffuse hair loss after administration of fluvoxamine and condition remitted after cessation of the drug. Our report suggests the possibility of developing alopecia with fluvoxamine use.
Portuguese Journal of Dermatology and Venereology
Drugs are a relatively common cause of diffuse, nonscarring hair loss. They may interfere with the normal hair cycle, either by an abrupt cessation of the mitotic activity of matrix cells, causing anagen effluvium, or by an interruption of the anagen and a premature passage to the telogen phase, originating telogen effluvium. It is essential to obtain a complete history, including previous diseases and medications, focusing on the past 3 months, in order to rule out possible drug-induced alopecia. This review encompasses the most frequently involved drugs, including mechanisms of action and clinical characteristics of drug-induced alopecia. The correct recognition of drug-induced alopecia is essential since the main approach is to stop the offending agent, whenever it is possible.
Diffuse Hair Loss Induced by Sertraline Use
Case Reports in Psychiatry, 2015
Hair loss is a rare side effect of psychotropic drugs. The most related drug class with this side effect is the mood stabilizers. Studies reporting the sertraline-induced alopecia are limited in number. Sertraline is a potent antidepressant which inhibits the serotonin reuptake from the presynaptic terminals selectively. The reason for hair loss could not be elucidated completely. Psychotropic drugs are usually considered to lead to hair loss through influencing the telogen phase of hair follicle. This paper reports a 21-year-old male with diffuse hair loss induced by sertraline use and improved by quitting the drug. To the best of our knowledge, there are no other case reports on sertraline-induced alopecia within 2 weeks.
Essitalopram kullanımıyla gelişen ve duloksetine geçilmesiyle gerileyen alopesi: Olgu sunumu
Dusunen Adam: The Journal of Psychiatry and Neurological Sciences, 2016
Alleviation of alopecia after switching from escitalopram to duloxetine: a case report Many psychotropic drugs, including SSRIs, lithium, carbamazepine, valproate, vigabatrin, antipsychotics, benzodiazepines, and tricyclic antidepressants have been implicated in cases with alopecia. Drugs may cause a variety of dermatological side effects, ranging from mild hair loss to total alopecia, from hypertrichosis to hirsutism. In this paper, we present a case where alopecia emerged due to escitalopram, and where this side effect was alleviated after switching to duloxetine; we also review the literature for antidepressantrelated alopecia.
[CASE] Essitalopram Kullanımıyla Gelişen ve Duloksetine Geçilmesiyle Gerileyen Alopesi: Olgu Sunumu
Düşünen Adam: Psikiyatri ve Nörolojik Bilimler Dergisi, 2016
Seçici serotonin geri alım inhibitörleri (SSGİ), lityum, karbamazepin, valproik asit (sodyum valproat), vigabatrin, antipsikotikler, benzodiazepinler, trisiklik antidepresanlar da dahil olmak üzere bir çok psikotrop ilacın saç kaybı ile ilişkili olduğu bildirilmiştir. İlaçlar hafif saç dökülmesinden saçların tamamen kaybına, hipertrikozisten hirsutizme kadar birçok saç hastalığına neden olabilir. Bu yazıda essitalopram kullanımıyla gelişen ve duloksetin tedavisine geçilmesiyle saç dökülmesi yan etkisi gerileyen bir olgu sunulmuş ve antidepresanlara bağlı alopesi ile ilgili alanyazın gözden geçirilmiştir. Alleviation of Alopecia After Switching to Duloxetine From Escitalopram: A Case Report Many psychotropic drugs, including SSRIs, lithium, carbamazepine, valproate, vigabatrine, antipsychotics, benzodiazepines, tricyclic antidepressants have been implicated in cases with alopecia. Drugs may cause a variety of dermatological side effects, ranging from mild hair loss to total alopecia, from hypertrichosis to hirsutism. In this paper, we present a case where alopecia emerged due to escitalopram, and where this side effect alleviated after switching to duloxetine, and we also review the literature for antidepressant related alopecia.
Journal of Analytical Toxicology, 2002
Hair samples of psychiatric patients were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS-MS) for the neuroleptics clozapine, flupentixol, haloperidol, penfluridol, thioridazine, and zuclopenthixol. In the study, these neuroleptics were administered to the patients regularly for a minimum of six months. Sample preparation was performed by washing, powdering with a ball mill, extraction of drugs from hair by ultrasonication with methanol, cleanup by solid-phase extraction and subsequent LC-MS-MS analysis using multiple reaction monitoring (MRM). Calibration was performed for all drugs in the range of 0.05 to 10 ng/mg using spiked hair powder and doxepin-d3 as internal standard. Twenty to 50 mg of hair powder was used and the detection limits of LC-MS-MS were below 0.05 ng/mg for all drugs tested. Therapeutic dosage, number of subjects, hair color, and detected amounts of drugs were as follows: dozapine (150-400 mg/day; n = 3, light brown, medium brown, black; 0.47-0.92 ng/mg), haloperidol (150 rag/3 weeks; n = 1, black/gray; 12.2 ng/mg), penfluridol (20-30 rag/week; n = 2, medium brown, black; 0.08 ng/mg; not detected in one case), thioridazine (100-400 rag/day; n-4, light brown, medium brown, black; 0.33-9.91 ng/mg, not detected in one case). Besides the active drugs also the desmethyl-metabolites of clozapine and thioridazine were detected by LC-MS-MS. However, flupentixol (5 rag/day; light brown hair) and zuclopenthixol (350 rag/3 weeks; light brown hair) were not detected by these methods in one case each, although the drugs were administered regularly to these patients. The comparison of dosage and hair color in two cases with thioridazine and penfluridol suggests that other interindividual factors may have an influence on drug concentration in hair.
To check the occurrence of Extrapyramidal Symptoms (EPS) and Hyperprolactinemia (HP) in Schizophrenic patients receiving Risperidone drug and to check the efficacy of the drugs used for the management of these side effects. The study assumes significance in light of reported data that anticholinergic drugs are not very effective in relieving side effects and that they may impair efficacy of antipsychotic drugs to relieve positive symptoms. Thirty one Schizophrenic patients receiving Risperidone drug were assessed for EPS & HP using Simpson Angus Rating Scale (SAS), Barnes Akathisia Rating Scale (BARS), Abnormal Involuntary Movement Scale (AIMS) & estimating prolactin level in blood. The EPS and HP side effects were treated with Trihexiphenidyl, propranolol or diazepam and cabergoline respectively and efficacy was studied for resolving the symptoms. The study revealed that 54.83% of patients on Risperidone showed EPS; majority of these patients (48.38%) developed Parkinsonism and rest (6.45%) developed Akathisia. Besides, 6.45% of the patients developed HP manifested as amenorrhea and menstrual irregularities. Trihexiphenidyl brought about resolution of most (88%) patients with Parkinsonism and partial resolution in remaining patients where tremors & rigidity persisted. propranolol and diazepam brought about the resolution of Akathisia. Cabergoline brought about satisfactory resolution of HP & associated symptoms in all the cases. About 65% of the patients receiving risperidone drug exhibited perceptible side effects. EPS, particularly Parkinsonism was found to be the major adverse effect. All the side effects were adequately resolved by the conventional drugs even at lower levels of the recommended dose improving the compliance of the treatment.
Gratis Journal of Biomedical Sciences, 2015
To check the occurrence of Extrapyramidal Symptoms (EPS) and Hyperprolactinemia (HP) in Schizophrenic patients receiving Risperidone drug and to check the efficacy of the drugs used for the management of these side effects. The study assumes significance in light of reported data that anticholinergic drugs are not very effective in relieving side effects and that they may impair efficacy of antipsychotic drugs to relieve positive symptoms. Thirty one Schizophrenic patients receiving Risperidone drug were assessed for EPS & HP using Simpson Angus Rating Scale (SAS), Barnes Akathisia Rating Scale (BARS), Abnormal Involuntary Movement Scale (AIMS) & estimating prolactin level in blood. The EPS and HP side effects were treated with Trihexiphenidyl, propranolol or diazepam and cabergoline respectively and efficacy was studied for resolving the symptoms. The study revealed that 54.83% of patients on Risperidone showed EPS; majority of these patients (48.38%) developed Parkinsonism and rest (6.45%) developed Akathisia. Besides, 6.45% of the patients developed HP manifested as amenorrhea and menstrual irregularities. Trihexiphenidyl brought about resolution of most (88%) patients with Parkinsonism and partial resolution in remaining patients where tremors & rigidity persisted. propranolol and diazepam brought about the resolution of Akathisia. Cabergoline brought about satisfactory resolution of HP & associated symptoms in all the cases. About 65% of the patients receiving risperidone drug exhibited perceptible side effects. EPS, particularly Parkinsonism was found to be the major adverse effect. All the side effects were adequately resolved by the conventional drugs even at lower levels of the recommended dose improving the compliance of the treatment.